Department of Intensive Medicine, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, 341000, China.
Department of Pathogenic Biology, School of Basic Medical Sciences, Gannan Medical University, Ganzhou, 341000, China.
BMC Infect Dis. 2020 Dec 11;20(1):952. doi: 10.1186/s12879-020-05678-0.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, and outbreaks have occurred worldwide. Laboratory test results are an important basis for clinicians to determine patient condition and formulate treatment plans.
Fifty-two thousand six hundred forty-four laboratory test results with continuous values of adult inpatients who were diagnosed with COVID-19 and hospitalized in the Fifth Hospital in Wuhan between 16 January 2020 and 18 March 2020 were compiled. The first and last test results were compared between survivors and non-survivors with variance test or Welch test. Laboratory test variables with significant differences were then included in the temporal change analysis.
Among 94 laboratory test variables in 82 survivors and 25 non-survivors with COVID-19, white blood cell count, neutrophil count/percentage, mean platelet volume, platelet distribution width, platelet-large cell percentage, hypersensitive C-reactive protein, procalcitonin, D-dimer, fibrin (ogen) degradation product, middle fluorescent reticulocyte percentage, immature reticulocyte fraction, lactate dehydrogenase were significantly increased (P < 0.05), and lymphocyte count/percentage, monocyte percentage, eosinophil percentage, prothrombin activity, low fluorescent reticulocyte percentage, plasma carbon dioxide, total calcium, prealbumin, total protein, albumin, albumin-globulin ratio, cholinesterase, total cholesterol, nonhigh-density/low-density/small-dense-low-density lipoprotein cholesterol were significantly decreased in non-survivors compared with survivors (P < 0.05), in both first and last tests. Prothrombin time, prothrombin international normalized ratio, nucleated red blood cell count/percentage, high fluorescent reticulocyte percentage, plasma uric acid, plasma urea nitrogen, cystatin C, sodium, phosphorus, magnesium, myoglobin, creatine kinase (isoenzymes), aspartate aminotransferase, alkaline phosphatase, glucose, triglyceride were significantly increased (P < 0.05), and eosinophil count, basophil percentage, platelet count, thrombocytocrit, antithrombin III, red blood cell count, haemoglobin, haematocrit, total carbon dioxide, acidity-basicity, actual bicarbonate radical, base excess in the extracellular fluid compartment, estimated glomerular filtration rate, high-density lipoprotein cholesterol, apolipoprotein A1/ B were significantly decreased in non-survivors compared with survivors (P < 0.05), only in the last tests. Temporal changes in 26 variables, such as lymphocyte count/percentage, neutrophil count/percentage, and platelet count, were obviously different between survivors and non-survivors.
By the comprehensive usage of the laboratory markers with different temporal changes, patients with a high risk of COVID-19-associated death or progression from mild to severe disease might be identified, allowing for timely targeted treatment.
新型冠状病毒病(COVID-19)由严重急性呼吸系统综合征冠状病毒 2 引起,已在全球范围内暴发。实验室检测结果是临床医生判断患者病情和制定治疗方案的重要依据。
收集 2020 年 1 月 16 日至 3 月 18 日期间在武汉市第五医院住院的确诊 COVID-19 成年患者的连续值实验室检测结果,共 52644 例。采用方差检验或 Welch 检验比较存活者和非存活者的首诊和末次检测结果。对差异有统计学意义的实验室检测变量进行时间变化分析。
在 82 例存活者和 25 例非存活者的 94 项实验室检测变量中,白细胞计数、中性粒细胞计数/百分比、血小板平均体积、血小板分布宽度、血小板大细胞百分比、超敏 C 反应蛋白、降钙素原、D-二聚体、纤维蛋白(原)降解产物、中荧光网织红细胞百分比、幼稚网织红细胞百分比、乳酸脱氢酶明显升高(P<0.05),而淋巴细胞计数/百分比、单核细胞百分比、嗜酸性粒细胞百分比、凝血酶原活性、低荧光网织红细胞百分比、血浆二氧化碳、总钙、前白蛋白、总蛋白、白蛋白、白蛋白/球蛋白比值、胆碱酯酶、总胆固醇、非高密度/低密度/小而密低密度脂蛋白胆固醇明显降低(P<0.05),首诊和末次检测结果均如此。凝血酶原时间、凝血酶原国际标准化比值、有核红细胞计数/百分比、高荧光网织红细胞百分比、血浆尿酸、血浆尿素氮、胱抑素 C、钠、磷、镁、肌红蛋白、肌酸激酶同工酶、天门冬氨酸氨基转移酶、碱性磷酸酶、血糖、甘油三酯明显升高(P<0.05),而嗜酸性粒细胞计数、嗜碱性粒细胞百分比、血小板计数、血小板压积、抗凝血酶 III、红细胞计数、血红蛋白、红细胞压积、总二氧化碳、酸碱、实际碳酸氢根、细胞外液碱剩余、估计肾小球滤过率、高密度脂蛋白胆固醇、载脂蛋白 A1/B 明显降低(P<0.05),仅在末次检测中如此。淋巴细胞计数/百分比、中性粒细胞计数/百分比和血小板计数等 26 项变量的时间变化在存活者和非存活者之间明显不同。
通过综合使用具有不同时间变化的实验室标志物,可以识别 COVID-19 相关死亡风险较高或从轻症向重症发展的患者,从而进行及时的靶向治疗。